RxDoctor Payments Data

Kenneth Carr, MD

Cardiovascular Disease · Oceanside, CANPI 1245255439

Payments from drug & device makers

$106,306in general payments, 2019–2025

Across 135 payments — averaging $787.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$46K
  • Boehringer Ingelheim International GmbH$27K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$13K
  • AstraZeneca$10K
  • Esperion Therapeutics, Inc.$5K
  • Novartis$4K
  • plus $2K from 14 others
$4,089in research payments, 2019–2025

Across 4 payments — averaging $1022.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Kowa Research Institute, Inc.$4K

What the payments were for

  • Travel & lodging$70522%
  • Food & beverage$2,41077%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,306 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$291,365
Medicare patients
774
Services billed
3,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$227,983
FarxigaDapagliflozin Propanediol37$53,336
EntrestoSacubitril/Valsartan36$44,684
XareltoRivaroxaban25$32,905
JardianceEmpagliflozin29$29,719
Repatha SureclickEvolocumab20$29,515
VascepaIcosapent Ethyl33$21,994
Icosapent Ethyl39$16,057
BrilintaTicagrelor14$15,229
Ezetimibe228$4,700
Rosuvastatin Calcium393$3,911
Metoprolol Succinate241$3,693
ClopidogrelClopidogrel Bisulfate151$2,437
Potassium Chloride94$2,011
Losartan Potassium175$1,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$9,634$68,56451 claims
NovartisEntresto$3,601$44,68436 claims
Johnson & JohnsonXarelto$19$32,90525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →